APPORT DU FACTEUR DE CROISSANCE ÉPIDERMIQUE HUMAIN RECOMBINANT INJECTÉ EN INTRA- LÉSIONNEL DANS LE TRAITEMENT DES PLAIES CHRONIQUES.

The use of recombinant human factor in intralesional diabetic foot has been the subject of several studies that have proven its effectiveness, to the extent of avoiding amputation. Its effectiveness on chronic wounds is currently being studied, with relevant results. We analyzed the results of a series of patients with chronic wounds treated in the Plastic Surgery Department of the Mohammed VI Medical Center in Marrakech. This is a prospective study conducted between January and April 2019, involving ten patients with chronic wounds, who benefited from intra- and peri-lesional infiltration of recombinant human factor. The average age was 48.8 years with extremes of 17 and 69 years. All our patients were male. 80% of our patients lived in adverse conditions. The average duration of the lesions was 8.1 years with extremes ranging from 6 months to 37 years. The average size of the loss of substance was 10.4 cm2 with extremes ranging from 04 to 18 cm2. The etiologies of the loss of substance were variable, dominated by loss of substance post-accident on a public road in more than 60% of the cases. 40% of our patients reported pain at the level of the site and 20% vertigo. Evolution of the lesions was regularly evaluated by clinical examination and photographs. Budding was obtained in 30% of the cases after grafting, epidermalization in 40% of the cases, and a very significant reduction in the size of the loss area in 30% of cases. The use of recombinant human factor is one of the encouraging therapeutic advances in regenerative medicine that has proven effective on chronic wounds with a reduced overall cost. [ABSTRACT FROM AUTHOR]